Levetiracetam Tablet, Film Coated
Product Images NDC 43063-617

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43063-617). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063617 Label (43063617)

Label for Levetiracetam USP oral film-coated tablets, 500 mg strength, containing 60 tablets per bottle. The label includes the NDC 43063-617-60 and shows PD-Rx Pharmaceuticals, Inc. as the labeler based in Oklahoma City, OK. Additional information includes lot number SAMPLE and expiration date 01/50. The label also contains usage directions fields and a warning to keep the product out of reach of children.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 01

A text panel showing the formula for calculating total daily dose (mL/day) of a medication based on daily dose (mg/kg/day), patient weight (kg), and concentration (100 mg/mL). This is a typical dosing calculation instruction for oral liquid medications.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 02

A text panel showing a formula for calculating creatinine clearance (CLcr) based on age, weight, and serum creatinine, including adjustment for female patients and for body surface area (BSA). It details the steps and variables involved in the calculation.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 03

Chemical structure diagram of the active ingredient levetiracetam showing its molecular components including a pyrrolidone ring and side chains.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 04

A bar graph comparing the percentage of patients across three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). The y-axis represents the percentage of patients ranging from 0% to 45%.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 05

A bar graph illustrating the percentage of patients in three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The graph compares patient response rates across these treatment categories.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 06

A bar graph comparing the percentage of patients between two groups: Placebo (N=104) with 14.4% and Levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 07

A bar chart comparing the percentage of patients between Placebo (N=97) and Levetiracetam (N=101). The chart shows 19.6% of patients in the Placebo group and 44.6% of patients in the Levetiracetam group, with the y-axis labeled as % of Patients.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 08

A bar chart comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The vertical axis represents the percentage of patients ranging from 0% to 45%. The Placebo group shows 19.6%, while the Levetiracetam group shows 43.1%. An asterisk is marked above the Levetiracetam bar, indicating statistical significance or emphasis.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 09

A vertical bar chart showing the percentage of patients for two groups: Placebo (N=84) at 45.2% and Levetiracetam (N=79) at 72.2%. The y-axis represents the percentage of patients ranging from 0% to 100%. The Levetiracetam bar includes an asterisk (*) above the percentage value.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.